| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 06/27/2002 | WO2002050096A1 Sodium-channel alpha1-subunit and their polypeptides and their treatment of generalised epilepsy with febrile seizures plus |
| 06/27/2002 | WO2002050084A2 Streptogramin derivatives preparation thereof and compositions containing same |
| 06/27/2002 | WO2002050056A1 Benzylamine derivatives and their use as thrombin inhibitors |
| 06/27/2002 | WO2002050051A1 Chemical compounds |
| 06/27/2002 | WO2002050019A2 Diamines as modulators of chemokine receptor activity |
| 06/27/2002 | WO2002049676A2 Compositions containing inclusion complexes |
| 06/27/2002 | WO2002049671A1 Recombinant serum albumin for use in cleansing or dermatological products for skin or hair |
| 06/27/2002 | WO2002049665A2 Use of activated coagulation factor vii for treating thrombolytic therapy-induced major bleedings |
| 06/27/2002 | WO2002049664A1 Direct delivery of a gene product to the hypothalamus |
| 06/27/2002 | WO2002049663A2 Compositions and methods for manipulating glial progenitor cells and treating neurological deficits |
| 06/27/2002 | WO2002049662A2 Use of the prion protein (prp) for suppression of bax-mediated apoptosis |
| 06/27/2002 | WO2002049625A2 Compounds that affect cd83 expression, pharmaceutical compositions comprising said compounds and methods for identifying said compounds |
| 06/27/2002 | WO2002049617A2 Self forming, thermodynamically stable liposomes and their applications |
| 06/27/2002 | WO2002049611A2 Ophthalmic lubricating solution adapted for use in lasik surgery |
| 06/27/2002 | WO2002049603A1 Compositions for prevention and alleviation of skin wrinkles |
| 06/27/2002 | WO2002049593A2 Use of dna repair enzymes as mmp-1 inhibitors |
| 06/27/2002 | WO2002049577A2 Analogues of thiocoraline and be-22179 |
| 06/27/2002 | WO2002049576A2 Fab i and inhibition of apicomplexan parasites |
| 06/27/2002 | WO2002049575A2 Method and composition for the treatment of diabetic neuropathy |
| 06/27/2002 | WO2002049501A2 Local regional chemotherapy and radiotherapy using in situ hydrogel |
| 06/27/2002 | WO2002030393A3 Polymeric delivery formulations of leuprolide with improved efficacy |
| 06/27/2002 | WO2002026935A3 TGF-β INHIBITORS AND METHODS |
| 06/27/2002 | WO2002026932A3 Rna aptamers and methods for identifying the same |
| 06/27/2002 | WO2002020822A3 Biopanning and rapid analysis of selective interactive ligands (brasil) |
| 06/27/2002 | WO2002020566A3 NOVEL MMP-2 DERIVATIVES FOR USE AS INHIBITORS OF INTEGRIN αVβ¿3? |
| 06/27/2002 | WO2002016548A3 Novel g protein-coupled receptor |
| 06/27/2002 | WO2002016415A3 Identification of a cam-kinase ii inhibitor |
| 06/27/2002 | WO2002015881A3 Use of a porous carrier |
| 06/27/2002 | WO2002006821A3 Antimicrobial agent |
| 06/27/2002 | WO2002005844A3 Protein complex serving as a vehicle for orally administerable medicaments |
| 06/27/2002 | WO2002002597A3 Peptide extended glycosylated polypeptides |
| 06/27/2002 | WO2002002053A3 Anticancer transgenic tomato |
| 06/27/2002 | WO2002000882A3 Transport peptides dirived from erns protein, cytotoxic rnase of ribosome-inactivating protein or a rsv g-protein and analogues thereof |
| 06/27/2002 | WO2001098536A3 METHOD FOR ACTIVATING PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR-$g(g) |
| 06/27/2002 | WO2001097752A3 Compositions comprising urokinase for modulating muscle contractility and angiogenisis |
| 06/27/2002 | WO2001096286A3 Urokinase inhibitors |
| 06/27/2002 | WO2001094570A3 Transfection method |
| 06/27/2002 | WO2001094381A3 Novel compounds of the n-acylamino-amide family, compositions comprising same, and uses |
| 06/27/2002 | WO2001089509A3 Method of treating hiv-1 disease |
| 06/27/2002 | WO2001087938A3 Polynucleotide sequence encoding a putative cell adhesion molecule |
| 06/27/2002 | WO2001085949A3 Compounds and methods for the diagnosis and treatment of ehrlichia infection |
| 06/27/2002 | WO2001085215A3 METHODS OF MODULATING FUNCTIONS OF POLYPEPTIDE GalNAc TRANSFERASES AND OF SCREENING SUBSTANCES THEREFOR, PHARMACEUTICAL COMPOSITIONS COMPRISING SUCH AGENTS |
| 06/27/2002 | WO2001083746A3 Regulatory nucleic acid sequences of the abc1 gene |
| 06/27/2002 | WO2001081555A3 Human kinases |
| 06/27/2002 | WO2001081361B1 Compositions and method for diagnosing and treating conditions, disorders, or diseases involving cell death |
| 06/27/2002 | WO2001078781A8 Methods for prevention and treatment of gastrointestinal disorders |
| 06/27/2002 | WO2001076640A3 Chemically modified novel erythropoietin stimulating protein compositions and methods |
| 06/27/2002 | WO2001073027A3 Compositions and methods for therapy and diagnosis of colon cancer |
| 06/27/2002 | WO2001073025A3 Anti-angiogenic and anti-tumor properties of vascostatin and other nidogen domains |
| 06/27/2002 | WO2001072975A3 Human methyl transferase family member, 25552, and uses thereof |
| 06/27/2002 | WO2001072827A3 33395, a human leucine-rich repeat family member and use thereof |
| 06/27/2002 | WO2001070978A3 Polypeptides and nucleic acids encoding same |
| 06/27/2002 | WO2001057186A3 Methods and compositions for diagnosis and treatment of cancer based on esf |
| 06/27/2002 | WO2001054680A3 Method for using potassium channel activation for delivering a medicant to an abnormal brain region and/or a malignant tumor |
| 06/27/2002 | WO2001049847A9 26904, 38911, and 39404, seven-transmembrane proteins/g-protein coupled receptors |
| 06/27/2002 | WO2001040277A3 Carbohydrate-aminated glycoproteins |
| 06/27/2002 | WO2001030393A8 Methods for reducing the effects of cancers that express a33 antigen using a33 antigen specific immunoglobulin products |
| 06/27/2002 | WO2001026605A3 Immunosuppressive composition containing il-2 inhibitor and an adenosine deaminase inhibitor |
| 06/27/2002 | WO2001014536A3 Nucleic acid molecule comprising a nucleic acid sequence which codes for a haemocyanin, and comprising at least one intron sequence |
| 06/27/2002 | WO2001013908A9 Tissue volume reduction |
| 06/27/2002 | WO2001012217A9 Therapeutic antibody against muc-1 antigen and methods for their use |
| 06/27/2002 | WO2000077238A9 Heterodimeric opioid g-protein coupled receptors |
| 06/27/2002 | WO2000071561A9 Cd4-independent hiv envelope proteins as vaccines and therapeutics |
| 06/27/2002 | WO2000069879A9 Ca7 cg04 gene |
| 06/27/2002 | WO2000064925A9 Method of inhibiting leukocyte adhesion to fibrinogen |
| 06/27/2002 | WO2000064920A9 Compositions, methods, and kits relating to resistin |
| 06/27/2002 | WO2000059924A9 Methods and reagents for modulating caspase-mediated apoptosis |
| 06/27/2002 | WO2000056350A9 Methods of use of beta 1-integrin inhibitors |
| 06/27/2002 | WO2000056345A9 Methods for limiting scar and adhesion formation |
| 06/27/2002 | US20020083489 DNA molecules and polypeptides of pseudomonas syringae Hrp pathogenicity island and their uses |
| 06/27/2002 | US20020083477 Treating nerve damage; administer insulin like growth factor isoform to human, monitor response of damaged nerves |
| 06/27/2002 | US20020082694 Highly-mineralized osteogenic sponge compositions, and uses thereof |
| 06/27/2002 | US20020082620 Bioactive materials for aneurysm repair |
| 06/27/2002 | US20020082571 Method of using lectins for agglutination and collection of menstrual flow |
| 06/27/2002 | US20020082415 Antisense oligonucleotide modulation of human serine/threonine protein phosphatase gene expression |
| 06/27/2002 | US20020082413 PGC-1, a novel brown fat PPARgamma coactivator |
| 06/27/2002 | US20020082412 Methods |
| 06/27/2002 | US20020082409 Stresscopins and their uses |
| 06/27/2002 | US20020082408 GSK3 polypeptides |
| 06/27/2002 | US20020082402 Chlamydia antigens and corresponding DNA fragments and uses thereof |
| 06/27/2002 | US20020082401 Nucleotide sequences coding protein for use in treating eating disorder, autoimmune and viral diseases |
| 06/27/2002 | US20020082395 Immunoglobulin for use in diagnosis, treatment and prevention of bacterial infections |
| 06/27/2002 | US20020082393 Polypeptides for use as wound healing agent and bactericide |
| 06/27/2002 | US20020082388 Polypeptide for use in the treatment, diagnosis and prevention of cancer, nervous system and developmental disorders |
| 06/27/2002 | US20020082387 Novel proline-rich membrane protein |
| 06/27/2002 | US20020082385 Protein for use in dietetics and the treatment of diabebtes |
| 06/27/2002 | US20020082305 Petrolatum-based nose ointment |
| 06/27/2002 | US20020082290 Treating eye condition with an angiogenesis inhibitor, EM-138, 2-(1,3-dicarboxylpropyl)isoindolin-1-one |
| 06/27/2002 | US20020082235 Inhibition of binding of hox and homeodomain-containing proteins and uses thereof |
| 06/27/2002 | US20020082234 Novel prokaryotic polynucleotides, polypeptides and their uses |
| 06/27/2002 | US20020082233 Polynucleotides (with nucleotide sequence operably linked to an expression control sequence) encoding the human IL-11 receptor and fragments |
| 06/27/2002 | US20020082231 Utilizing ratC polypeptides to screen for antibacterial compounds |
| 06/27/2002 | US20020082230 Introducing an antisense oligomer into a cell, allowing the oligomer to hybridize to the mRNA of IL-15, thereby inhibiting the production of IL-15 |
| 06/27/2002 | US20020082229 ErbB4 receptor-specific neuregulin related ligands and uses therefor |
| 06/27/2002 | US20020082228 Specific oligonucleotides (8-50 nucleobses) hybridize with nucleic acids encoding BH3 Interacting domain Death agonist |
| 06/27/2002 | US20020082226 Antisense antibacterial method and composition |
| 06/27/2002 | US20020082225 Enzymatic nucleic acid treatment of diseases or conditions related to hepatitis c virus infection |
| 06/27/2002 | US20020082224 Non-immunogenic prodrugs and selectable markers for use in gene therapy |
| 06/27/2002 | US20020082219 Dendroaspis(green mamba snake) natriuretic peptide has at least one activity selected from the group consisting of vasodilation, antriuresis, diuresis and renin-suppressing activity |
| 06/27/2002 | US20020082217 Synthetic compounds, antibodies that recognize and bind to these compounds, polynucleotides that encode these compounds, and immune effector cells raised in response to presentation of these epitopes |